Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Ryan Cross

Senior Science Correspondent

Andrew Dunn

Senior Biopharma Correspondent

Earlier Tuesday, Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup launches: Xaira Therapeutics, which has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Ryan Cross

Senior Science Correspondent

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

Major PBM reforms feature in Congress' year-end spending bill

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up

Senior Science Correspondent

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup